Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients
| Autor: | Antonio Collado, José A. Girón, Mercedes González-Serrano, Luis F. López-Cortés, Juan A. Pineda, José A. Mira, Dolores Merino, José del Valle, María J. Ríos-Villegas, Antonio Rivero, Ignacio Santos, José A. García-García |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-HIV Agents Hepacivirus Hepatitis C virus Immunology HIV Infections Interferon alpha-2 medicine.disease_cause Antiviral Agents Gastroenterology Virus Polyethylene Glycols chemistry.chemical_compound Pegylated interferon Interferon Internal medicine Ribavirin Humans Immunology and Allergy Medicine Retrospective Studies biology medicine.diagnostic_test business.industry Cholesterol Interferon-alpha Cholesterol LDL Hepatitis C Chronic biology.organism_classification Lipids Recombinant Proteins Treatment Outcome Infectious Diseases chemistry RNA Viral Drug Therapy Combination Female business Lipid profile Biomarkers medicine.drug |
| Zdroj: | AIDS. 22:923-930 |
| ISSN: | 0269-9370 |
| DOI: | 10.1097/qad.0b013e3282ff8ad3 |
| Popis: | BACKGROUND High levels of serum low-density lipoprotein cholesterol are associated with better response to pegylated interferon and ribavirin in hepatitis C virus monoinfected patients. There are no data concerning this topic in HIV/hepatitis C virus coinfected patients in whom lipid disorders are particularly common. OBJECTIVE To assess the association between baseline lipid levels and sustained virologic response to pegylated interferon and ribavirin in coinfected patients. METHODS A total of 260 HIV/hepatitis C virus coinfected patients under treatment with pegylated interferon and ribavirin and who had a baseline serum lipid profile were included in this retrospective study. RESULTS Thirty-eight (24%) patients with genotypes 1-4 and 64 (63%) with genotypes 2-3 achieved sustained virologic response. Forty-nine (44%) patients with serum low-density lipoprotein cholesterol levels 100 mg/dl or more showed sustained virologic response compared with 53 (36%) with lower values [adjusted odds ratio: 2.51; 95% confidence interval: 1.40-4.87; P = 0.003]. This association was independent of the remaining predictors of sustained virologic response which were genotypes 2-3, plasma hepatitis C virus RNA 600,000 IU/ml or less, exposure to at least 80% of the planned therapy and lack of concomitant antiretroviral therapy. The rate of sustained virologic response in patients with genotype 1 and low-density lipoprotein cholesterol at least 100 mg/ml was 31% compared with 17% in those with lower values (adjusted odds ratio: 2.19; 95% confidence interval: 1.04-4.66; P = 0.040). The corresponding figures in subjects with genotypes 2-3 were 73 and 58% [2.71 (0.99-7.46); P = 0.054]. No other lipid was associated with response. CONCLUSION Higher low-density lipoprotein cholesterol levels predict sustained virologic response to pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients. This might be used to improve the rate of sustained virologic response in this setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|